Head-To-Head Survey: Pluristem Therapeutics (PSTI) vs. Cellular Dynamics International (ICEL)

Pluristem Therapeutics (NASDAQ: PSTI) and Cellular Dynamics International (NASDAQ:ICEL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of recent ratings for Pluristem Therapeutics and Cellular Dynamics International, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluristem Therapeutics 0 0 3 0 3.00
Cellular Dynamics International 0 0 0 0 N/A

Pluristem Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 172.11%. Given Pluristem Therapeutics’ higher possible upside, analysts clearly believe Pluristem Therapeutics is more favorable than Cellular Dynamics International.

Valuation & Earnings

This table compares Pluristem Therapeutics and Cellular Dynamics International’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pluristem Therapeutics $2.85 million 56.79 -$27.81 million ($0.32) -4.59
Cellular Dynamics International N/A N/A N/A ($1.94) -8.53

Cellular Dynamics International has lower revenue, but higher earnings than Pluristem Therapeutics. Cellular Dynamics International is trading at a lower price-to-earnings ratio than Pluristem Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Pluristem Therapeutics and Cellular Dynamics International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pluristem Therapeutics N/A -95.87% -77.80%
Cellular Dynamics International -88.12% -57.59% -38.09%

Insider and Institutional Ownership

4.2% of Pluristem Therapeutics shares are owned by institutional investors. 7.0% of Pluristem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


Pluristem Therapeutics beats Cellular Dynamics International on 8 of the 10 factors compared between the two stocks.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.

Cellular Dynamics International Company Profile

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply